A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

← catalyst calendar

NCT06820463 · readout ≤ 589 d

Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

390estimated

Sites

Countries

Australia, Austria, Brazil +11

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2025-04-24

actual

When the study began enrolling

Primary completion

Mar 2028

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Apr 2028

estimated

The whole study's end, after follow-up

First posted

2025-02-11

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-14

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Metastatic Colorectal Cancer

Interventions

Drug: Telisotuzumab Adizutecan
Drug: Fluorouracil
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Bevacizumab
Drug: Panitumumab

Primary outcomes

what the primary-completion date above is the date OF

Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.

measured Up to 24 Weeks

Number of Participants with Adverse Events (AE)s

measured Up to Approximately 6 Years

Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed